奥法木单抗联合苯丁酸氮芥治疗初治慢性淋巴细胞白血病的五年随访:Complement 1 III期试验最终分析
Complement 1 III期试验比较奥法木单抗联合苯丁酸氮芥与苯丁酸氮芥单药治疗初治慢性淋巴细胞白血病(CLL)的疗效与安全性。长期随访显示,联合组总生存风险估计降低12%(无统计学意义),无进展生存风险降低39%;两组后续治疗率均达61%,可能稀释OS差异。联合方案作为不适合含氟达拉滨治疗患者的一线选择,具有临床获益和耐受性,无新安全性问题。
要点
- 奥法木单抗联合苯丁酸氮芥一线治疗不适合含氟达拉滨方案的CLL患者有临床获益且耐受。
- 长期随访中联合组OS风险降低12%(无统计学意义),PFS风险降低39%。
- 两组后续治疗率均达61%,可能稀释OS差异并干扰OS结果解读。
核心结论
- 奥法木单抗联合苯丁酸氮芥作为不适合含氟达拉滨治疗CLL患者的一线选择,具有临床获益和耐受性,无新安全性问题。
研究设计与样本
- Complement 1为III期试验,比较奥法木单抗联合苯丁酸氮芥与苯丁酸氮芥单药治疗初治CLL患者,本文为五年随访最终分析。
主要发现
- 长期随访中,联合组较化疗组总生存风险估计降低12%(无统计学意义)。
- 联合组较化疗组无进展生存风险估计降低39%。
- 两组接受后续治疗的比例均高达61%。
临床怎么用
- 对于不适合含氟达拉滨治疗的初治CLL患者,可考虑奥法木单抗联合苯丁酸氮芥作为一线治疗选项。
局限性
- 两组后续治疗率均达61%,可能稀释潜在OS差异并干扰OS结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the chemoimmunotherapy arm vs. the chemotherapy arm there was an estimated 12% (not significant) and 39% risk reduction in overall survival and progression-free survival, respectively. A high rate (61%) of treatment with next-line therapies in both the treatment arms may dilute any potential OS difference and confound the interpretation of the OS results. Addition of ofatumumab to chlorambucil demonstrated clinical benefit and tolerability as a frontline treatment option in patients unfit for fludarabine-containing therapy, with no new safety concerns.
引用
- Offner F, Robak T, Janssens A, et al. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. Br J Haematol. 2020. PMID: 32236950. doi:10.1111/bjh.16625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。